ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2024

Elevated IgG4+ Plasmablasts In Patients With Active, Untreated IgG4-Related Disease

Zachary S. Wallace1, Vinay Mahajan2, Mollie Carruthers3, Hamid Mattoo4, Shiv Pillai5 and John H. Stone3, 1Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Massachusetts General Hospital, Boston, MA, 4Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Oncology, Massachusetts General Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IgG4 Related Disease, Plasmablasts and biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

IgG4-delated disease (IgG4-RD) is an immune-mediate condition responsible for inflammatory lesions that can affect nearly every organ.  Diagnosis is challenging as it relies upon classic histopathology and immunohistochemical findings as well as careful pathology interpretation and clinicopathologic correlation.  No single finding, including the IgG4+ plasma cell infiltrate or the serum IgG4 concentration, is diagnostic.  Paramount is the ability to distinguish IgG4-RD from clinically similar conditions such as malignancies.  A biomarker to identify patients with active disease would improve diagnosis and may help distinguish subtypes.  Here we describe the clinical characteristics of patients with active, untreated IgG4-RD and an elevated IgG4+ plasmablast level. 

Methods:

This study was approved by the institutional review board and all subjects provided informed, written consent. All patients had histopathologic proof and clinical features consistent with their IgG4-RD diagnoses. Nineteen IgG4-RD patients with active, untreated disease were evaluated and their blood sample findings were compared with those of ten healthy controls.  Patients’ disease activity was scored by the IgG4-RD Responder Index (RI) where an RI>/= 3 is regarded as active disease. Flow cytometry was used to measure absolute plasmablast count per ml by gating peripheral blood for IgG4+, CD19lowCD20–CD38+CD27+.  Serum IgG4 levels were measured by nephelometry. Student’s t-tests were used to compare the groups.

Results:

The mean age of the IgG4-RD group was 58 years (range: 41-77 years) and 14 (74%) were male.  Nine of the IgG4-RD patients had at least 3 organs involved; the remainder had active IgG4-RD in only 1 or 2 organs.  The mean IgG4-RD RI was 11.2 (range: 3-36).  The mean ages of the healthy controls was 42.5 years, six of whom were males. All of the IgG4-RD patients had an elevated IgG4+ plasmablast concentrations (normal <500 /ml; mean: 14,316 /ml; range: 732-85,208 /ml).  In contrast, the mean plasmablast concentration among healthy controls was 63/ml (range: 1-156/ml; p=0.02).  Among IgG4-RD patients, eight (42%) had normal serum IgG4 concentrations (nl< 135mg/dL; mean: 58.3 mg/dL; range: 5.3-123 mg/dL). The mean IgG4+ plasmablast concentration did not differ significantly according to the presence or absence of an elevated serum IgG4 concentration (means =14,249/ml & 13,169/ml, respectively; p=0.94).  Patients with a normal serum IgG4 concentration were more likely to have single organ disease as well as lower inflammatory markers; in contrast, patients with an elevated serum IgG4 concentration were more likely to have 3 or more organs involved (64% vs. 25%, p=0.10) and abnormal inflammatory markers (p<0.05 for C3 & CRP; p=0.15 for ESR & C4).  The serum plasmablast concentration correlated with the number of organs affected by IgG4-RD (R2= 0.80). 

Conclusion:

IgG4-RD appears to be associated with an elevated blood concentration of IgG4+ plasmablasts.  This finding may be highly specific for IgG4-RD and may be superior in sensitivity to the serum IgG4.  Further investigations of serum IgG4+ plasmablast concentrations in IgG4-RD and other immune mediated conditions are appropriate.


Disclosure:

Z. S. Wallace,
None;

V. Mahajan,
None;

M. Carruthers,
None;

H. Mattoo,
None;

S. Pillai,
None;

J. H. Stone,

Genentech and Biogen IDEC Inc.,

2,

Genentech and Biogen IDEC Inc.,

5,

Roche Pharmaceuticals,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-igg4-plasmablasts-in-patients-with-active-untreated-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology